BCIQ Profiles

Company Profile Report

Amunix’s Omega-led $73M A round to support shift to drug development

Fresh funding will support Amunix’s cancer pipeline, which applies polypeptide technology to T cell engagers

The potential for Amunix’s protein polymer technology to overcome toxicity issues that have plagued two growing immuno-oncology modalities convinced Omega Funds to lead the biotech’s $73 million series A. The round, together with cash from a January licensing deal with Roche, will fund Amunix’s pivot to drug development, enabling it to apply its XTEN platform towards an in-house pipeline of T

Read the full 617 word article

How to gain access

Continue reading with a
two-week free trial.